(Repeats to widen distribution, no change to headline or text)
NEW YORK, Sept 16 (Reuters) - A key safety trial of anexperimental Ebola vaccine manufactured by GlaxoSmithKline has injected 10 healthy volunteers since Sept. 2, Dr.Anthony Fauci of the National Institute of Allergy andInfectious Diseases told a U.S. Senate panel on Tuesday, and sofar "no red flags" indicating serious adverse reactions havebeen found.
An additional 10 volunteers will receive the vaccine incoming days.
The trial is being conducted at the National Institutes ofHealth Clinical Center in Bethesda, Maryland. Results areexpected by the end of this year.
The vaccine does not contain the actual Ebola virus, butonly one of its genes.
Researchers will determine not only whether the vaccinecauses adverse reactions but also whether it triggers theproduction of antibodies against the deadly virus, which haskilled more than 2,200 people in West Africa in the worst Ebolaepidemic ever recorded. (Reporting by Sharon Begley; Editing by Diane Craft)
Glaxosmithkline (GSK)